October 21, 2019 03:07 PM EDTUpdated October 22, 10:08 AM

The FDA sets a regulatory speed record, providing a snap OK for Vertex's breakthrough triplet for cystic fibrosis

John Carroll

Editor & Founder

The FDA has approved Vertex’s new triplet for cystic fibrosis at a record-setting speed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

The FDA sets a regulatory speed record, providing a snap OK for Vertex's breakthrough triplet for cystic fibrosis

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Supreme Court weighs in on Purdue Pharma's bankruptcy, with an eye toward opioid victims

Updated: Roche buys obesity and diabetes biotech Carmot Therapeutics in $2.7B merger deal

Roche's BTK inhibitor put on partial hold over concerns about potential liver injury

Novartis unveils new brand identity after Sandoz spinoff

Wet AMD biotech stock soars over 200% as lead asset matches Regeneron’s Eylea in PhII test

Early prediction of outcomes in DLBCL clinical trials through MRD testing

The FDA sets a reg­u­la­to­ry speed record, pro­vid­ing a snap OK for Ver­tex's break­through triplet for cys­tic fi­bro­sis

John Carroll

Editor & Founder

Unlock this article instantly by becoming a free subscriber.

Supreme Court weighs in on Pur­due Phar­ma's bank­rupt­cy, with an eye to­ward opi­oid vic­tims

Up­dat­ed: Roche buys obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics in $2.7B merg­er deal

Roche's BTK in­hibitor put on par­tial hold over con­cerns about po­ten­tial liv­er in­jury

No­var­tis un­veils new brand iden­ti­ty af­ter San­doz spin­off

Wet AMD biotech stock soars over 200% as lead as­set match­es Re­gen­eron’s Eylea in PhII test

Ear­ly pre­dic­tion of out­comes in DL­B­CL clin­i­cal tri­als through MRD test­ing

The FDA sets a regulatory speed record, providing a snap OK for Vertex's breakthrough triplet for cystic fibrosis

Supreme Court weighs in on Purdue Pharma's bankruptcy, with an eye toward opioid victims

Updated: Roche buys obesity and diabetes biotech Carmot Therapeutics in $2.7B merger deal

Roche's BTK inhibitor put on partial hold over concerns about potential liver injury

Novartis unveils new brand identity after Sandoz spinoff

Wet AMD biotech stock soars over 200% as lead asset matches Regeneron’s Eylea in PhII test

Early prediction of outcomes in DLBCL clinical trials through MRD testing